Neurokinin receptor antagonists

被引:25
作者
Elliott, J
Seward, EM
机构
[1] Merck/Sharp/Dohme Research Labs., Neuroscience Research Centre, Essex CM20 2QR, Terlings Park
关键词
neurokinin; tachykinin; substance P;
D O I
10.1517/13543776.7.1.43
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The competitive area of neurokinin (NK) receptor antagonists has recently seen the publication of early clinical results which provide strong support for their use in the treatment of pain, emesis and asthma. Preclinical models support their use in a number of additional disorders including anxiety, arthritis, migraine, cancer and schizophrenia. New indications, such as glaucoma and ocular hypotension, neuronal injury and stroke, cardiac disorders and topical applications have recently been claimed. Published patent applications from most of the major pharmaceutical companies claim a wide variety of structural classes as antagonists at all three neurokinin receptors. This review discusses the significance of new clinical data for ongoing drug discovery efforts, and patent claims for new indications and new structural classes for the period since the last review in early 1996.
引用
收藏
页码:43 / 54
页数:12
相关论文
共 44 条
  • [1] ACHARD D, 1996, 25 NAT MED CHEM S AN
  • [2] THE DISTRIBUTION OF SUBSTANCE-P AND 5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM OF THE DOG
    AMIN, AH
    CRAWFORD, TBB
    GADDUM, JH
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1954, 126 (03): : 596 - 618
  • [3] RESINFERATOXIN, AN ULTRAPOTENT CAPSAICIN ANALOG, HAS ANTIEMETIC PROPERTIES IN THE FERRET
    ANDREWS, PLR
    BHANDARI, P
    [J]. NEUROPHARMACOLOGY, 1993, 32 (08) : 799 - 806
  • [4] Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound.
    Armour, DR
    Chung, KML
    Congreve, M
    Evans, B
    Guntrip, S
    Hubbard, T
    Kay, C
    Middlemiss, D
    Mordaunt, JE
    Pegg, NA
    Vinader, MV
    Ward, P
    Watson, SP
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (09) : 1015 - 1020
  • [5] The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist
    Beattie, DT
    Beresford, IJM
    Connor, HE
    Marshall, FH
    Hawcock, AB
    Hagan, RM
    Bowers, J
    Birch, PJ
    Ward, P
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) : 3149 - 3157
  • [6] GR159897, A POTENT NONPEPTIDE ANTAGONIST AT TACHYKININ NK2 RECEPTORS
    BERESFORD, IJM
    SHELDRICK, RLG
    BALL, DI
    TURPIN, MP
    WALSH, DM
    HAWCOCK, AB
    COLEMAN, RA
    HAGAN, RM
    TYERS, MB
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 272 (2-3) : 241 - 248
  • [7] BURCKHOLDER TP, 1996, BIOORG MED CHEM LETT, V6, P951
  • [8] Neurokinin receptor antagonists for the treatment of inflammation
    Carruthers, NI
    Kaminski, JJ
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (02) : 169 - 174
  • [9] Morphan based substance P antagonists
    Cocker, JD
    Davies, HG
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (01) : 13 - 16
  • [10] DIENER HC, 1995, 6 INT HEAD RES SEM C